The ongoing DARK-Sepsis trial (ClinicalTrials.gov NCT05824767) is designed to examine whether baseline renin and DPP3 levels can predict response to angiotensin II therapy compared with standard vasopressor management in patients with vasodilatory shock requiring norepinephrine [73]. Here, AGT is linked to Sepsis.